Clinical trial ASCENT-04
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Gilead Science |
EudraCT Identifier | 2021-005742-14 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05382286 |
Last update |